Lora Stanka Kirigin Bilos

Dr. Lora Stanka Kirigin Bilos


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

Verified
Journal Article
Open access
PDF file
VAVelimir Altabas
Velimir Altabas
LBLora Stanka Kirigin Bilos
Lora Stanka Kirigin Bilos
Cardiovascular complications are associated with advanced atherosclerosis. Although atherosclerosis is still regarded as an incurable disease, at least in its more advanced stages, the discovery of endothelial progenitor cells (EPCs), with their ability to replace old and injured cells and differentiate into healthy and functional mature endothelial cells, has shifted our view of atherosclerosis as an incurable disease, and merged traditional theories of atherosclerosis pathogenesis with evolving concepts of vascular biology. EPC alterations are involved in the pathogenesis of vascular abnormalities in atherosclerosis, but many questions remain unanswered. Many currently available drugs that impact cardiovascular morbidity and mortality have shown a positive effect on EPC biology. This review examines the role of endothelial progenitor cells in atherosclerosis development, and the impact standard antilipemic drugs, including statins, fibrates, and ezetimibe, as well as more novel treatments such as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulating agents and angiopoietin-like proteins (Angtpl3) inhibitors have on EPC biology.

13 July 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LVLjubica Vazdar
Ljubica Vazdar
IGIvo Darko Gabrić
Ivo Darko Gabrić
IKIvan Kruljac
Ivan Kruljac
HPHrvoje Pintarić
Hrvoje Pintarić
RŠRobert Šeparović
Robert Šeparović
MŠMario Štefanović
Mario Štefanović
Trastuzumab has improved the prognosis of HER2 positive breast cancer, but cardiotoxicity remains a concern. We aimed to identify risk factors for trastuzumab-induced cardiotoxicity, with an emphasis on the HER2 Ile655Val single nucleotide polymorphism. This single-center case–control study included 1056 patients with early-stage HER2 positive breast cancer that received adjuvant trastuzumab. Cardiotoxicity was defined as a decline in left ventricular ejection fraction (LVEF) > 15% in patients without previous cardiomyopathy, or > 10% in patients with baseline LVEF of < 50%. Patient characteristics and cardiac parameters were compared in 78 (7.38%) cases and 99 randomly assigned controls, and the polymorphism was genotyped using real-time polymerase chain reaction. Cardiotoxicity was independently associated with advanced age (P = 0.024), lower body mass index (P = 0.023), left breast involvement (P = 0.001), N3 status (P = 0.004), diabetes (P = 0.016), and a family history of coronary artery disease (P = 0.019). Genotype distribution was as follows: A/A (Ile/Ile) was found in 111 (62.7%) patients, A/G (Ile/Val) in 60 (33.9%) patients, and G/G (Val/Val) in 6 (3.4%) patients. The genotype was not associated with cardiotoxicity or the severity of heart failure, reversibility, and recovery time. We found no association between the HER2 Ile655Val polymorphism and trastuzumab-induced cardiotoxicity; therefore, we do not recommend routine cardiotoxicity-risk stratification using this polymorphism.

1 January 2016 in Acta Clinica Croatica
Verified
Journal Article
Open access
PDF file
LBLora Stanka Kirigin Bilos
Lora Stanka Kirigin Bilos
MNMarko Nikolić
Marko Nikolić
IKIvan Kruljac
Ivan Kruljac
DMDomagoj Marjan
Domagoj Marjan
IPIvan Penavić
Ivan Penavić
MVMilan Vrkljan
Milan Vrkljan
Internal hernias have an overall incidence of less than 1% and are difficult to diagnose clinically due to their nonspecific presentation. Most internal hernias present as strangulating closed-loop obstruction and delay in surgical...

1 August 2019 in World Neurosurgery
Verified
Journal Article
Closed access
LBLora Stanka Kirigin Bilos
Lora Stanka Kirigin Bilos
IKIvan Kruljac
Ivan Kruljac
JRJelena Marinković Radošević
Jelena Marinković Radošević
MĆMiroslav Ćaćić
Miroslav Ćaćić
IŠIvan Škoro
Ivan Škoro
MVMilan Vrkljan
Milan Vrkljan